Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 8/20 | 0.72 |
| ▸ | NTRK3 | Q16288 | 6/20 | 0.72 |
| ▸ | NTRK2 | Q16620 | 6/20 | 0.72 |
| ▸ | FYN | P06241 | 10/20 | 0.56 |
| ▸ | PIM1 | P11309 | 1/20 | 0.56 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.53 |
| ▸ | JAK2 | O60674 | 1/20 | 0.52 |
| ▸ | ABL1 | P00519 | 1/20 | 0.52 |
| ▸ | INSR | P06213 | 1/20 | 0.52 |
| ▸ | LCK | P06239 | 1/20 | 0.52 |
| ▸ | CSF1R | P07333 | 1/20 | 0.52 |
| ▸ | LYN | P07948 | 1/20 | 0.52 |
| ▸ | RET | P07949 | 1/20 | 0.52 |
| ▸ | IGF1R | P08069 | 1/20 | 0.52 |
| ▸ | MET | P08581 | 1/20 | 0.52 |
| ▸ | ROS1 | P08922 | 1/20 | 0.52 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.52 |
| ▸ | FGR | P09769 | 1/20 | 0.52 |
| ▸ | KIT | P10721 | 1/20 | 0.52 |
| ▸ | SRC | P12931 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3212412 | 0.84 | NTRK1 (0.71) | NTRK1NTRK3NTRK2FYNPIM1 | |
| SCHEMBL13223334 | 0.83 | NTRK1 (0.79) | NTRK1NTRK3NTRK2FYNPIM1 | |
| SCHEMBL3210730 | 0.83 | NTRK1 (0.75) | NTRK1NTRK3NTRK2FYNPIM1 | |
| SCHEMBL3196558 | 0.82 | NTRK1 (1.00) | NTRK1NTRK3NTRK2FYNPIM1 | |
| SCHEMBL3201414 | 0.80 | NTRK1 (1.00) | NTRK1NTRK3NTRK2FYNPIM1 | |
| SCHEMBL1053535 | 0.77 | FYN (0.80) | NTRK1NTRK3NTRK2FYNPIM1 | |
| SCHEMBL3196776 | 0.75 | NTRK1 (0.66) | NTRK1NTRK3NTRK2FYNPIM1 | |
| SCHEMBL19466727 | 0.75 | NTRK1 (0.68) | NTRK1NTRK3NTRK2FYNPIM1 | |
| SCHEMBL13223416 | 0.73 | NTRK1 (0.64) | NTRK1NTRK3NTRK2FYNPIM1 | |
| SCHEMBL13223399 | 0.73 | MKNK1 (0.73) | NTRK1NTRK3NTRK2FYNPIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100041662-A1 | Heterocyclic compounds as antiinflammatory agents | FERRAND SANDRINE | 2010-02-18 | — | — | US | disclosed |
| EP-2089393-A1 | HETEROCYCLIC COMPOUNDS AS ANTIINFLAMMATORY AGENTS | Novartis AG (CH) | 2009-08-19 | — | — | EP | disclosed |
| WO-2008052734-A1 | HETEROCYCLIC COMPOUNDS AS ANTIINFLAMMATORY AGENTS | NOVARTIS AG (CH) | 2008-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041662-A1 | Heterocyclic compounds as antiinflammatory agents | JAK2, IRAK4, ALK | NTRK1 201/4885NTRK3 67/4885NTRK2 115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.